Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Eisai
Company Monitoring Page for Eisai
latest headlines for company on cafepharma
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 11:56 am
Tags:
Alzheimer's disease
,
Eli Lilly
,
Biogen
,
Eisai
,
Leqembi
,
donanemab
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Sun, 08/27/23 - 04:40 pm
Tags:
Merck
,
Eisai
,
Keytruda
,
Lenvima
,
clinical trials
,
head and neck cancer
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
Mon, 08/14/23 - 06:54 pm
Tags:
FDA
,
Alzheimer's disease
,
Eisai
,
Biogen
,
Leqembi
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Wed, 08/2/23 - 10:43 pm
Tags:
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Tags:
Eisai
,
Biogen
,
Leqembi
,
FDA
,
Alzheimer's disease
,
subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Tags:
Eli Lilly
,
donanemab
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
Tags:
CMS
,
Alzheimer's disease
,
Eisai
,
Biogen
,
PET scans
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Sun, 07/16/23 - 03:11 pm
Tags:
Alzheimer's disease
,
drug launches
,
Biogen
,
Eisai
,
Leqembi
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Thu, 07/13/23 - 10:16 am
Tags:
Biogen
,
Eisai
,
Leqembi
,
Alzheimer's disease
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Tags:
Eisai
,
Biogen
,
Leqembi
,
drug pricing
,
Medicare
,
Alzheimer's disease
Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod
Fierce Pharma
Tue, 07/11/23 - 11:20 pm
Tags:
Eisai
,
Alzheimer's disease
,
Leqembi
,
Ivan Cheung
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Tags:
Biogen
,
Eisai
,
Leqembi
,
FDA
,
Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
Tags:
FDA
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
,
SAGE Therapeutics
,
zuranolone
,
postpartum depression
,
major depressive disorder
,
Roche
,
Tecentriq
,
non-small cell lung cancer
,
CRISPR Therapeutics
,
Bluebird Bio
,
lovo-cel
,
exa-cel
,
BrainStorm Cell Therapeutics
,
NurOwn
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
Tags:
FDA
,
SAGE Therapeutics
,
Biogen
,
zuranolone
,
Eisai
,
Leqembi
,
Sanofi
,
AstraZeneca
,
nirsevimab
,
Iveric Bio
,
Zimura
,
Alnylam
,
Onpattro
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Fri, 06/23/23 - 10:03 am
Tags:
Biogen
,
Eisai
,
Alzheimer's disease
,
FDA
,
Leqembi
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Mon, 06/19/23 - 10:21 am
Tags:
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
,
Europe
On the Cusp of Full Approval, Leqembi’s Rollout Could Face Challenges
BioSpace
Fri, 06/16/23 - 10:01 am
Tags:
Eisai
,
Biogen
,
Alzheimer's disease
,
FDA
,
Leqembi
The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules
Forbes
Wed, 06/14/23 - 06:42 pm
Tags:
Alzheimer's disease
,
drug pricing
,
Medicare
,
Biogen
,
Eisai
,
Leqembi
Biopharma Confronts a Rising Tide of Ransomware Attacks
BioSpace
Wed, 06/14/23 - 10:11 am
Tags:
cyberattacks
,
cybersecurity
,
ransomware
,
Eisai
,
Sun Pharma
,
Novartis
,
AstraZeneca
,
Merck
Eisai goes after head and neck cancer in Made of More campaign
Medical Marketing and Media
Mon, 06/12/23 - 11:24 pm
Tags:
Eisai
,
head and neck cancer
,
pharma marketing
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
an umbrella protects you from: rain, sand, hunger
*
Fill in the blank.